Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ).

Trial Details

NCT ID
NCT03938987
Phase
PHASE1 / PHASE2
Sponsor
University of Alberta
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • autologous CD19-directed chimeric antigen receptor (CAR) T-cells
Locations (sample)
  • Calgary, Alberta, Canada|51.05011,-114.08529
  • Calgary, Alberta, Canada|51.05011,-114.08529
  • Calgary, Alberta, Canada|51.05011,-114.08529
  • Edmonton, Alberta, Canada|53.55014,-113.46871
  • Edmonton, Alberta, Canada|53.55014,-113.46871

Key Eligibility Criteria

  • Have given written informed consent prior to any study-specific procedures; children (defined as 17 years of age or less) require guardian consent.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; or Karnofsky \> 50%.
  • Age of 2 to 70 years at time of screening.
  • A histologically or cytologically documented, CD19+ non-hodgkin's lymphoma or ALL.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →